Safety of Serial Monthly Administration of Triple‐Dose Gadopentetate Dimeglumine in Multiple Sclerosis Patients: Preliminary Results of the BECOME Trial

Wolansky, Leo; Haghighi, Mohammad Hasan; Sevdalis, Evangelia; Cook, Stuart D.; Sethi, Nilay; Jiang, Leng; Joseph, George; Tulloch, Kimberly; Cadavid, Diego

doi:10.1111/j.1552-6569.2005.tb00326.x

Cited by 12 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary analysis of clinical adverse events showed a similar frequency as that reported in previous studies. 11 The frequency of lab abnormalities compared with baseline was significantly increased for five separate lab test results-low urine specific gravity, high blood glucose, high ALT, low WBC, and hypophosphatemia (Wolansky et al, Safety of monthly 3-dose Gd in patients with early forms of MS: Data from the BECOME trial. Proceedings of the ASNR 45th Annual Meeting.…”

Section: Introductionmentioning

confidence: 99%

Hypophosphatemia is Associated with the Serial Administration of Triple‐Dose Gadolinium to Patients for Brain MRI

Wolansky

Cadavid

Punia

et al. 2015

Journal of Neuroimaging

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Hypophosphatemia is Associated with the Serial Administration of Triple‐Dose Gadolinium to Patients for Brain MRI

Wolansky

Cadavid

Punia

et al. 2015

Journal of Neuroimaging

Self Cite

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2005

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

MRI demonstration of gadolinium deposition in bone after monthly triple-dose gadopentetate dimeglumine and correlation with frequency of hypophosphatemia

et al. 2021

View full text Add to dashboard Cite

Safety of Serial Monthly Administration of Triple‐Dose Gadopentetate Dimeglumine in Multiple Sclerosis Patients: Preliminary Results of the BECOME Trial

Cited by 12 publications

References 4 publications

Hypophosphatemia is Associated with the Serial Administration of Triple‐Dose Gadolinium to Patients for Brain MRI

Hypophosphatemia is Associated with the Serial Administration of Triple‐Dose Gadolinium to Patients for Brain MRI

Current awareness: Pharmacoepidemiology and drug safety

MRI demonstration of gadolinium deposition in bone after monthly triple-dose gadopentetate dimeglumine and correlation with frequency of hypophosphatemia

Contact Info

Product

Resources

About